PARP Inhibitors for Cancer Therapy
PARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARP-poly ADP ribose polymerase-in cancer therapy. The volume covers the history of the discovery of PARP and its role in DNA repair. Additionally, it describes the discovery of the PARP family, and includes a discus...
Call Number: | Libro Electrónico |
---|---|
Corporate Author: | |
Other Authors: | , |
Format: | Electronic eBook |
Language: | Inglés |
Published: |
Cham :
Springer International Publishing : Imprint: Humana,
2015.
|
Edition: | 1st ed. 2015. |
Series: | Cancer Drug Discovery and Development,
|
Subjects: | |
Online Access: | Texto Completo |
Table of Contents:
- History of the discovery of poly (ADP-ribose)
- Discovery of the PARP superfamily and focus on the lesser exhibited but not lesser talented members
- The role of PARPs in DNA Strand Break Repair
- TIPs: Tankyrase Interacting Proteins
- PARP and Carcinogenesis
- Multitasking roles for poly(ADP-ribosyl)ation in aging and longevity
- Overview of PARP Inhibitor Design and Optimization
- Structure Based Design of PARP Inhibitors
- Preclinical chemosensitization by PARP inhibitors
- Classification of PARP inhibitors based on PARP trapping and catalytic inhibition, and rationale for combinations with topoisomerase I inhibitors and alkylating agents
- Radiosensitisation by poly(ADP-ribose) polymerase inhibition
- The vasoactivity of PARP inhibitors
- Synthetic lethality with Homologous Recombination Repair defects
- Targeting tumour hypoxia with PARP Inhibitors: Contextual synthetic lethality
- Other determinants of sensitivity
- Synthetic sickness with molecularly targeted agents against the EGFR pathway
- Disruption of DNA repair by cell cycle and transcriptional CDK inhibition
- Resistance to PARP Inhibitors Mediated by Secondary BRCA1/2 Mutations
- PARP inhibitor resistance - what is beyond BRCA1 or BRCA2 restoration
- Introduction to PARPi clinical trials and future directions
- Clinical trials investigating PARP inhibitors as single agents
- Clinical trials of PARP inhibitors with chemotherapy
- Combination of PARP inhibitors with clinical radiotherapy
- Biomarkers for PARP Inhibitors.